Open AccessSuccessful treatment of severe cholinergic urticaria with omalizumab: A case report
Author(s) -
Yamasaki Aoi,
Oda Yoshiko,
Tanizaki Hideaki,
Otsuka Toshihiro,
Fukunaga Atsushi,
Nishigori Chikako,
Moriwaki Shinichi
Publication year - 2019
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12043
Subject(s) - omalizumab , medicine , antihistamine , chronic urticaria , dermatology , adverse effect , immunoglobulin e , immunology , antibody
Abstract Omalizumab, a humanized anti‐IgE monoclonal antibody, has been approved in Japan for the treatment of antihistamine‐resistant idiopathic chronic spontaneous urticaria. We herein report a 27‐year‐old Japanese woman suffering from a 2‐year history of severe cholinergic urticaria (sweat allergy‐type), which was unresponsive to various H2‐antihistamines and other medication but was successfully treated with omalizumab. The patient showed rapid and marked reduction in her symptoms of urticaria after the first injection of omalizumab (300 mg). She has been receiving omalizumab treatment quaque 4 weeks (q4w) three times and subsequent q6w six times, followed by maintenance treatment q8w without any adverse reactions for a total of 68 weeks. Although further large‐scale clinical investigation is needed, omalizumab may be a beneficial therapeutic remedy for patients with intractable, chronic inducible urticaria including cholinergic urticaria.